Replies to post #22746 on OncoSec Medical Inc (ONCSQ)

[lasers]

Has nothing to do with $ONCS. BMY is a competitor of Merck. $ONCS tech is EP+IL-12. $ONCS proposed Combo is for their EP+IL-12 in combination with PD-1/PD-L1

[furbush87]

I responded to that over on YMB, it had to have been posted by someone that does not know how to read or do DD. Comparing trial data PD1 drugs have better response rates but also more SAE's, some can not complete treatment as a result. On top of that, and more importantly is the fact that PD1 drugs are what ImmunoPulse is supposed to enhance.
to say BMY beat ONCS to the punch would be like saying we don't need cars because exxon already makes gas.